阿德福韦酯、恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效分析

目的探讨阿德福韦酯、恩替卡韦治疗HBeAg阳性慢性乙型肝炎的疗效。方法选择本院收治的HBeAg阳性慢性乙型肝炎患者60例,随机分为研究组与对照组,研究组30例患者给予恩替卡韦0.5mg,每晚空腹口服,对照组30例患者给予阿德福韦酯10mg,每日1次口服。两组均治疗1年,观察治疗效果。结果治疗前两组性别、年龄、ALT、HBV-DNA水平比较,差异无统计学意义（P〉0.05）,治疗6、12个月时研究组HBeAg阴转率、HBeAg血清学转换率均高于对照组,差异有统计学意义（P〈0.05）;治疗6、12个月时两组ALT复常率比较,差异均无统计学意义（P〉0.05）;治疗12个月后两组HBVDNA低于103拷贝/mL的患者比例比较,差异有统计学意义（P〈0.05）;两组治疗中均未见明显药物不良反应,均无因药物不良反应停药者,治疗12个月后复查血肾功能均正常。结论恩替卡韦治疗HBeAg阳性慢性乙型肝炎病毒学和生化疗效较好,可用慢性乙型肝炎一线抗病毒治疗。

Effect analysis of Adefovir dipivoxil and Entecavir in treatment of chronic hepatitis B patients with positive HBeAg

Objective To evaluate the effect of Adefovir Dipivoxil and Entecavir in treatment of patients with HBeAg-positive chronic hepatitis B.Methods Sixty cases of chronic hepatitis B patients with positive HBeAg were randomly divided into study group and control group,30 patients in study group were treated with Entecavir 0.5 mg,oral per night,30 patients of control group were treated with Adefovir 10 mg,oral one time a day.Both groups were treated for one year and then the therapeutic effect was observed.Results The data of sex,age,ALT,HBV-DNA level of two groups before treatment were not significantly different(P > 0.05);HBeAg negative rate,HBeAg seroconversion rates of study group were higher after 6 and 12 months treatment than those of control group,the differences were statistically significant(P < 0.05),but there was no significant difference in ALT normalization rate between the two groups after 6 and 12 months treatment(P > 0.05);after 12 months treatment,patients with HBV DNA less than 103 copies/ml in two groups had significant difference(P < 0.05);there was no significant adverse drug reactions,drug stoping,and the function of blood and kidney were normal after 12 months treatment.Conclusion The efficacy of Entecavir in treatment of chronic hepatitis B patients with positive HBeAg is good,it is available for first-line anti-viral treatment of chronic hepatitis.